An observational study in Diabetic Nephropathies, Kidney Diseases and Renal Insufficiency, Chronic, sponsored by University of Pennsylvania. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-02.
Sponsored by University of Pennsylvania · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 153 studies in Diabetic Nephropathies with a site in United States — 22 open to participants now, 32 under way, 1 of them phase 3. Diabetic Nephropathies · United States.
Among the 153 studies in Diabetic Nephropathies with a site in United States, this one is the 15th largest by planned enrollment of the 31 observational ones that give a count, is one of 6 that started in 2025, is one of 31 observational ones, reaches primary completion later than 16 of the 30 other live ones, and was the 152nd registered.
544 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.
Browse Diabetic Nephropathies studies →22 of the 153 studies in Diabetic Nephropathies with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–80
Medical University of South Carolina · Sites in United States
Ages 18–75
AstraZeneca · Sites in United States
Ages 18–75 · Healthy volunteers
Seattle Children's Hospital · Sites in United States
Ages 14–40
Mayo Clinic · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
153 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 61 · Phase 3 16 · Phase 4 10
First in 1981; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is close to the median of 188 across 138 observational studies indexed under Diabetic Nephropathies.
Median enrollment 79 across the 120 interventional studies, 175 across the 31 observational. Of the 115 that completed or were terminated, 46 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
70 of 153 have an industry lead sponsor. The 10 most frequent:
University of Pennsylvania is the lead sponsor of 1,668 studies on the registry; 229 are open to participants now.
Of its 160 completed or terminated interventional studies of FDA-regulated products, 110 (69%) have results posted.
University of Pennsylvania has 2 studies filed under Diabetic Nephropathies — fewer than ten, so there is no comparison to draw.
12 of the studies in Diabetic Nephropathies with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05759468Brigham and Women's HospitalNAD Augmentation in Diabetes Kidney Disease | 2026-11-30 |
| NCT07022418Medical University of South CarolinaFormoterol in Diabetes | 2026-12 |
| NCT04802395Renalytix AI, Inc.Real World Evidence Clinical Utility Study of KidneyIntelX | 2026-12-01 |
| NCT05507892University of Colorado, DenverRenal Mechanism of SGLT2 Inhibition | 2026-12-15 |
| NCT07024823AstraZenecaA Study to Investigate Safety, Tolerability, PK, and PD of AZD4248 in Healthy Participants, Participants With CKD and Type 2 Diabetes, Assess Home Measurements of Creatinine in a Non-Interventional Cohort, and Assess the Effect of AZD4248 on the PK of Midazolam and Metformin in Healthy Participants | 2027-01-29 |
Add all 12 to your calendar (.ics) → With an account.
Among the 153 studies in Diabetic Nephropathies with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn more about kidney health in adults with diabetic kidney disease and other groups. Researchers will study kidney tissue and other samples. They want to learn how sodium-glucose cotransporter-2 (SGLT2) inhibitors, a type of diabetes medicine, may affect the kidneys. People can join only if they are already having a kidney biopsy or kidney surgery as part of their regular medical care.
The main questions this study aims to answer are:
Researchers will compare participants who take SGLT2 inhibitors with similar participants who do not take these medicines.
Participants will:
Let researchers use one stored slide of kidney tissue from their regular care (no extra research biopsy) Give a blood sample and a urine sample Let researchers review medical record information over time
TRIDENT 2.0 is a multicenter observational translational study that characterizes kidney molecular and histopathologic features in relation to exposure to kidney-protective therapies, with a focus on sodium-glucose cotransporter-2 (SGLT2) inhibitors. The study leverages archived clinical kidney pathology material and harmonized clinical data to support integrated molecular-histologic analyses across participating sites.
Tissue sources and central repository workflows:
Formalin-fixed, paraffin-embedded (FFPE) kidney tissue sections/slides are generated from archived clinical pathology material (including clinically indicated kidney biopsies and available donor or nephrectomy specimens) and transferred under coded identifiers to a central repository for downstream molecular assays and digital pathology.
Spatial transcriptomics and molecular profiling:
Spatially resolved transcriptomic methods are used to generate high-resolution molecular maps while preserving tissue architecture. FFPE (or fresh-frozen, when available) sections may be processed using commercially available spatial transcriptomics platforms (e.g., 10x Genomics Visium, NanoString CosMx, Xenium) or updated technologies implemented under study governance. Standard quality control procedures evaluate tissue integrity, RNA quality, capture efficiency, and resolution of major kidney compartments and cell types. Sequencing is performed on Illumina platforms with platform-appropriate depth, followed by preprocessing using platform-specific pipelines and downstream analysis in R/Python workflows (e.g., Seurat or equivalent) with normalization and batch correction as needed. Planned analyses include identification of cell-type and sub-cell-type signatures in spatial context, mapping of injury patterns (e.g., fibrosis/inflammation/vascular remodeling), and comparative molecular profiling across disease categories and therapy exposure groups with adjustment for relevant covariates.
Digital pathology and centralized histopathology review:
Digitized clinical stains and available diagnostic images are used for centralized review and standardized lesion scoring by renal pathologists. When applicable, diabetic kidney disease (DKD) is classified using established renal pathology criteria. Specimen adequacy metrics are used to guide analytic inclusion and sensitivity analyses.
Linked clinical data (high level):
Clinical data are harmonized across sites to support clinicopathologic and molecular integration, including medication exposure history and relevant laboratory and diagnostic variables. Longitudinal clinical information is used to contextualize molecular and histologic findings for downstream modeling.
Statistical and integrative analytic approach:
Analytic methods include differential expression and pathway analyses with appropriate multiple-testing control and covariate adjustment. Integrative modeling may combine molecular, histologic, and clinical domains using dimension reduction and regularized approaches to derive molecular signatures associated with disease state and therapy exposure.
TRIDENT 2.0 will enroll approximately 200 participants across multiple sites. Eligible participants include:
All participants must provide informed consent for release of one H\&E slide from their clinical biopsy or surgical specimen and for abstraction of relevant clinical data.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults with diabetic kidney disease confirmed by a clinically indicated kidney biopsy. This cohort is used to evaluate kidney molecular and histopathologic features in relation to medication exposure history. Interventions/exposures of interest (observational): Primary exposure is sodium-glucose cotransporter 2 inhibitors; additional therapy exposures of interest include renin-angiotensin-aldosterone system blockade, glucagon-like peptide-1 receptor agonists, mineralocorticoid receptor antagonists, and other therapies.
Drug: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) · Drug: Renin-angiotensin-aldosterone system blockade · Drug: Glucagon-like peptide-1 receptor agonists (GLP 1 RA) · Drug: Mineralocorticoid Receptor Antagonists(MRAs)
Adults with other forms of kidney disease (non-DKD), included as disease controls for cross-disease comparisons of molecular and histologic patterns. Interventions/exposures of interest (observational): Medication exposure history is captured to support comparisons across therapy classes, including SGLT2 inhibitors and other disease-modifying therapies.
Drug: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) · Drug: Renin-angiotensin-aldosterone system blockade · Drug: Glucagon-like peptide-1 receptor agonists (GLP 1 RA) · Drug: Mineralocorticoid Receptor Antagonists(MRAs)
Living kidney donors with available donor biopsy tissue, included as a comparator group to provide reference kidney tissue profiles. Interventions/exposures of interest (observational): Medication exposure history (including kidney-protective therapies where applicable) may be used in descriptive and comparative analyses; donors primarily serve as a reference/control tissue cohort.
Drug: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) · Drug: Renin-angiotensin-aldosterone system blockade · Drug: Glucagon-like peptide-1 receptor agonists (GLP 1 RA) · Drug: Mineralocorticoid Receptor Antagonists(MRAs)
Adults undergoing nephrectomy with non-tumor, adjacent normal kidney tissue available, included as a control/reference tissue cohort. Interventions/exposures of interest (observational): Medication exposure history (including SGLT2 inhibitors and other kidney-protective therapies) may be incorporated in comparative analyses across cohorts.
Drug: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) · Drug: Renin-angiotensin-aldosterone system blockade · Drug: Glucagon-like peptide-1 receptor agonists (GLP 1 RA) · Drug: Mineralocorticoid Receptor Antagonists(MRAs)
Standard-of-care exposure to sodium-glucose cotransporter 2 inhibitors documented from medication history. Participants are not assigned therapy. Exposure status is used for observational comparisons of kidney tissue molecular and histopathologic features.
Also known as: SGLT2 inhibitors
Standard-of-care exposure to renin-angiotensin-aldosterone system blockade documented from medication history for observational comparisons.
Standard-of-care exposure documented from medication history for observational comparisons.
Also known as: GLP-1 receptor agonists
Standard-of-care exposure documented from medication history for observational comparisons.
Also known as: MRAs
Change in Kidney Tissue molecular fingerprint
Change/differences in kidney tissue molecular "fingerprint" (molecular pathways / spatial gene expression signatures derived from archived kidney tissue) comparing participants exposed to sodium-glucose cotransporter 2 inhibitors versus controls and participants on other therapies. Tissue profiling includes single-cell spatial transcriptomics with differential expression and pathway analyses stratified by therapy exposure.
Time frame: Baseline enrollment to 18 months.
Change in estimated glomerular filtration rate (eGFR)
Change in eGFR calculated using the 2021 race-free CKD-EPI equation.
Time frame: Baseline to 18 months
Change in urine protein/creatinine ratio
Change in urine protein/creatinine ratio over follow-up.
Time frame: Baseline to 6 months.
Descriptive histopathology features and spatial gene expression patterns across cohorts
Descriptive histopathological features (fibrosis, sclerosis, inflammation, vascular changes) and spatial gene expression patterns evaluated across diabetic kidney disease, disease controls, donor, and nephrectomy cohorts.
Time frame: At enrollment/baseline (Single assessment on the archived clinical specimen slide)
Associations between histopathological features and clinical outcomes
Associations between histopathological features and clinical outcomes including eGFR slope, proteinuria, kidney failure, and transplant.
Time frame: Up to 3 years (longitudinal outcome abstraction, including dialysis/transplant/kidney failure/mortality as captured).
Associations between histopathological features and prior medication exposures
Associations between histopathological features and prior medication exposures, including SGLT2 inhibitors, renin-angiotensin-aldosterone system blockade, glucagon-like peptide-1 receptor agonists, mineralocorticoid receptor antagonists, and other therapies.
Time frame: Baseline (prior/current medication exposure history at enrollment).
Feasibility metrics
Accrual rate by cohort, proportion of slides successfully retrieved, and slide quality metrics.
Time frame: During study accrual and specimen acquisition (up to 3 years).
Started Nov 2025 (actual). Primary completion is estimated for May 2027, 18 months after the start.
Of 38 observational studies under Diabetic Nephropathies, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 25. This study's planned 18 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.